Fig. 4

Predictive value of plasma ctDNA for treatment response. A Box plot showing the distribution of plasma ctDNA levels in patients with complete response (CR) and non-CR. B Higher ctDNA levels are associated with worse treatment response. (C) Mutation profiles of MCL patients grouped by treatment response, using plasma ctDNA for genotyping. (D) Bar plots depicting the proportion of CR and non-CR patients with TP53 mutations or genetic alterations in the BCR/TLR signaling. (E) Comparison of ctDNA levels (using the median as the cutoff) and plasma-based TP53 mutations in predicting treatment response, relative to the MCL International Prognostic Index (MIPI). (F) The proportion of CR and non-CR patients stratified by ctDNA levels, using the median ctDNA level as the cutoff. (G) The proportion of CR patients in subgroups stratified by both ctDNA level and the presence of TP53 mutations